Experimental prostate cancer vaccine trial halted early
NCT ID NCT05617040
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested an experimental immunotherapy called VTP-850 in 22 men whose prostate cancer had returned (shown by rising PSA levels) after initial treatment like surgery or radiation. The therapy used two modified viruses to train the immune system to attack prostate cancer cells. The study was terminated early, so its full safety and effectiveness are unknown.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VTP-850 (a two-part vaccine using a chimpanzee adenovirus and a modified vaccinia virus to train the immune system against prostate cancer proteins)
What this could lead to
If it had succeeded, this could have pointed toward a new way to delay or avoid stronger treatments for men with early prostate cancer recurrence.
What could go wrong
The trial was terminated early, so results are limited. It was also a small, early-phase study, so even if completed, success was not guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Carolina Urologic Research Center
Myrtle Beach, South Carolina, 29572, United States
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
-
Cornell University
New York, New York, 10065-4805, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
University of Virginia Health System
Charlottesville, Virginia, 22908, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States